EQS-Adhoc: BRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservative development for the second half of the fiscal year 2024/25

BRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservative development for the second half of the fiscal year 2024/25

Zwingenberg, Germany, 30 April 2024 – BRAIN Biotech AG (ISIN DE0005203947; “BRAIN” or “Company”) today reports preliminary Q2 figures for the financial year 2024/25 with Q2 revenues of EUR 12.12 million and an adjusted EBITDA of minus EUR 0.36 million. The publication of the comprehensive half year reporting for 31 March 2025 (6M) and the analyst call will take place as previously scheduled on May 28^th, 2025.

Due to the overall weaker economic environment and strong USD currency fluctuations the Company now forecasts full-year 2024/25 revenues for the core segment BRAINBiocatalysts to be around the level of last year and therefore below the original guidance. The guidance for the adjusted EBITDA margin in the segment BRAINBiocatalysts and the guidance for the segment BRAINBioIncubator remains unchanged.

Notifying person:

Martina Schuster
BRAIN Biotech AG
– Investor Relations –
Darmstädter Str. 34-36
64673 Zwingenberg
Deutschland

www.brain-biotech-group.com

Investor Relations Office
Tel.: +49-(0)-6251-9331-0
Fax: +49-(0)-6251-9331-11
E-Mail: ir@brain-biotech.com